Thank You for Your Service
The 2026 edition of the long-running optometric pharmaceutical guide, authored by Ron Melton, OD, and Randall Thomas, OD, marks the final installment of the publication after more than 30 years of service to the profession. The guide, which provides clinical road maps for ocular medications, includes a new 100-question assessment and contributions from guest experts on myopia and age-related macular degeneration (AMD).
Did You Know? The “drug guide” originated in May 1992 as a lengthy article written by Drs. Melton and Thomas, two North Carolina-based practitioners, before being expanded into a recurring supplement due to its success in helping optometrists navigate evolving pharmaceutical prescribing rights.
Evolution of Medical Optometry
The transition of optometry toward increased pharmaceutical involvement began in the early 1990s as states began adopting Therapeutic Pharmaceutical Agent (TPA) laws. According to records from the period, the addition of prescribing rights created a significant learning curve for many practitioners who were previously unaccustomed to managing medical cases. Drs. Melton and Thomas, who gained clinical experience through military service, emerged as leaders in this shift by lecturing on ocular pharmaceuticals and documenting clinical procedures.
Expert Insight: The Legacy of Clinical Education
Expert Insight: The departure of Drs. Melton and Thomas signals the end of a foundational era in optometric education. By bridging the gap between scientific literature and “in the trenches” clinic hours, their guide served as a primary resource for practitioners adapting to expanded medical scopes. The inclusion of a 100-question quiz in the final edition suggests a focus on ensuring that the clinical principles they championed remain accessible for future self-testing and professional development.
Expert Contributions and Future Scope
The 2026 guide expands beyond the core work of its primary authors by inviting specialized perspectives. Ashley Tucker, OD, and Kevin Chan, OD, provide analysis regarding the myopia epidemic, while Leo Semes, OD, offers insights into contemporary AMD therapies. This multi-author approach reflects the increasing specialization within the field of eye care.
What May Happen Next
With the permanent retirement of the Melton and Thomas guide, the profession may see a shift in how clinical pharmaceutical knowledge is disseminated. As these authors step back from their long-term project, it is likely that future clinical resources will need to adapt to include the same blend of practical, experience-based advice and peer-reviewed literature that defined this series for three decades. While the authors continue to lecture and practice part-time, the conclusion of this publication marks a transition point for clinical reference standards in the industry.
Frequently Asked Questions
Who are the primary authors of the drug guide?
The guide was authored by Ron Melton, OD, and Randall Thomas, OD, both of whom have practiced for over 30 years and served as advocates for optometric medical eye care.
What is the purpose of the 100-question quiz in the 2026 edition?
The quiz is designed to allow optometrists to test their understanding of the clinical principles and pharmaceutical practices that Drs. Melton and Thomas have taught throughout their careers.
Will there be future installments of the Melton and Thomas guide?
No, the 2026 edition is the final installment of the guide, as the authors are stepping back from the project after more than three decades.
How will the loss of this long-standing clinical reference influence the way new optometrists approach medical eye care training?